Resistance treatment of nematrelvir/ritonavir combination (Nirmatrelvir/Ritonavir)

Nematrelvir/Ritonavir tablet combination Paxlovid (Nirmatrelvir/Ritonavir) is effective against the main variants of the new coronavirus, including the Omicron variant. The currently proposed resistance mechanism is the possibility of potential escape mutations. The nematvir/ritonavir combination is a combination of two drugs with different mechanisms of action.

The first ingredient, nematvir, is a peptidomimetic inhibitor of Mpro (the main protease of the new coronavirus). Inhibiting Mpro prevents the virus from processing the polyprotein precursors it needs to replicate. The second ingredient, ritonavir, is a human immunodeficiency virus-1 (HIV-1) protease inhibitor with CYP3A inhibition. This latter effect allows its use as a pharmacokinetic enhancer to reduce CYP3A-mediated metabolism of nematvir. Nematvir needs to be coadministered with ritonavir to increase the plasma concentration of nematvir enough to reach the target therapeutic range. Since everyone's constitution is different, their resistance to drugs is also different. If drug resistance occurs after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.

NematrevirThe combination of nematvir/ritonavir tablets has been launched in China. Due to its short time on the market, it has not been included in the medical insurance. The domestic price has not yet been determined. The original drug of nematvir/ritonavir tablet combination marketed overseas, the specification is nematvir 150mg + ritonavir 100mg)*30 tablets per box, the price may be around 2,000 yuan (the price may fluctuate due to the exchange rate), India The price of each box of the generic Nematvir/Ritonavir tablet combination produced by the pharmaceutical factory may be around RMB 1,000 (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same. For more drug information and specific prices, please consult Yaode Medical Consultant.